FREELINE
LIVE

Serial Number

79252849

Owner

Freeline Therapeutics Limited

Attorney

Samantha M. Quimby

Filing Date

Nov 19, 2018

Add to watchlist:

No watchlists yet
View on USPTO

FREELINE Trademark

Serial Number: 79252849 • Registration: 5974485

FREELINE is a trademark filed by Freeline Therapeutics Limited on November 19, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). The application is currently registered and active.

Owner Contact Info

Freeline Therapeutics Limited (4 trademarks)

Sycamore House,

Entity Type: 99

Trademark Details

Filing Date

November 19, 2018

Registration Date

February 4, 2020

Published for Opposition

November 19, 2019

Goods & Services

Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others

Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 4, 2025 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 4, 2023 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Aug 6, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 5, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 18, 2020 FICS
FINAL DISPOSITION PROCESSED
May 18, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 4, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 4, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 19, 2019 NPUB
PUBLISHED FOR OPPOSITION
Nov 19, 2019 PUBO
NOTIFICATION PROCESSED BY IB
Nov 15, 2019 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 30, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 30, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 30, 2019 NONP
ASSIGNED TO LIE
Oct 17, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 10, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 20, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 20, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 20, 2019 TROA
REFUSAL PROCESSED BY IB
Apr 6, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 21, 2019 RFCS
REFUSAL PROCESSED BY MPU
Mar 21, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 12, 2019 RFCR
NON-FINAL ACTION WRITTEN
Mar 11, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Mar 8, 2019 MAFR
ASSIGNED TO EXAMINER
Mar 4, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 4, 2019 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 1, 2019 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 28, 2019 REPR